Therese Phillips

Learn More
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non-small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. PD-L1 has(More)
AIMS Assessment of hormone receptor expression is part of routine examination of every breast cancer. In this study, we report the characterisation of a novel rabbit monoclonal antibody, clone EP1, directed against oestrogen receptor (ER) α. Additionally, its immunohistochemical performance characteristics in archival tissues are evaluated in normal tissues(More)
Recently, it has been shown that brain growth is characterized by periods of especially large increases in growth, with "plateaus" in growth between these "spurt" periods. In humans, these spurts in brain growth are correlated with spurts in mind growth, collectively termed phrenoblysis. Brain growth spurts in rodents occur at 0-6, 8-12, and 17-23 days of(More)
  • 1